| Zacks Company Profile for ARS Pharmaceuticals, Inc. (SPRY : NSDQ) |
|
|
| |
| • Company Description |
| ARS Pharmaceuticals Inc. is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions which could lead to anaphylaxis. The company is developing neffy(TM) an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications and insect bites. ARS Pharmaceuticals Inc., formerly known as Silverback Therapeutics Inc., is based in SEATTLE.
Number of Employees: 160 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $17.98 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,545,066 shares |
| Shares Outstanding: 98.21 (millions) |
| Market Capitalization: $1,765.88 (millions) |
| Beta: 0.90 |
| 52 Week High: $18.90 |
| 52 Week Low: $8.91 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
24.86% |
20.18% |
| 12 Week |
20.83% |
1.64% |
| Year To Date |
70.43% |
59.60% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Richard Lowenthal - President; Chief Executive Officer; and Director
Pratik Shah - Chairman of the Board of Directors
Kathleen D. Scott - Chief Financial Officer
Peter Kolchinsky - Director
Rajeev Dadoo - Director
|
|
Peer Information
ARS Pharmaceuticals, Inc. (GSAC)
ARS Pharmaceuticals, Inc. (CASI)
ARS Pharmaceuticals, Inc. (ALCD.)
ARS Pharmaceuticals, Inc. (OMNN)
ARS Pharmaceuticals, Inc. (CGPI.)
ARS Pharmaceuticals, Inc. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 82835W108
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
|
|
Share - Related Items
Shares Outstanding: 98.21
Most Recent Split Date: (:1)
Beta: 0.90
Market Capitalization: $1,765.88 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.41 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-1.44 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 5.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/05/25 |
|
|
|
| |
